報價延遲最少15分鐘:2024/06/01 03:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.12/-2.06
|
|
企業價值
133.21M
|
| 資產負債 |
|
每股賬面淨值
2.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/01 03:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the toolsof modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction. |